echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Lilly Cardiometabolic New Drug Domestic Clinical, Qilu, Novartis, Sanofi... RNAi therapy involved in the country?

    Lilly Cardiometabolic New Drug Domestic Clinical, Qilu, Novartis, Sanofi... RNAi therapy involved in the country?

    • Last Update: 2022-10-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 15, according to the official website of CDE, the clinical trial application submitted by Eli Lilly Cardiometabolic New Drug LY3819469 Injection in China was accepted (acceptance number: JXHL2200285


    From: CDE website

    Dicerna and Eli Lilly have reached a collaboration on 2 RNAi therapies into the clinical phase

    Dicerna and Eli Lilly have reached a collaboration on 2 RNAi therapies into the clinical phase

    LY3819469 is a new drug under development for cardiometabolic that has been approved by the FDA in May 2021 and is currently conducting a Phase I clinical study of cardiometabolic diseases (registration number: NCT04914546).


    LY3819469 is an RNAi drug


    Cardiometabolic, neurodegenerative diseases and pain

    Under the terms of the agreement, Dicerna will receive an advance payment of $100 million and an equity investment


    $350 million in development and promotion milestone payments

    The collaboration is primarily based on Dicera's proprietary GalXC™ RNAi technology, a technology platform designed to drive the development of the next generation of RNAi-based therapies to silence disease-causing genes


    Didrina's original RNAi technology platform was designed primarily for the field of liver disease, but Dcerna is currently exploring other areas, and its new application of RNAi technology and GalXC-Plus expands the function and application


    LY3819469 is the second clinical product developed by the two companies in cooperation with the second clinical stage product, after in November 2020, another RNAi therapy candidate of the company, LY3561774, has been approved by the FDA for clinical trial, and is currently conducting a phase II clinical study of hyperlipidemia (registration number: NCT05256654), which has not been reported to the domestic clinic


    LY3819469 Gantt chart of global development progress

    From: Insight Database Web (http://db.


    In addition to the two products, which are already in the clinical stage, the two companies are also working together to advance the development of multiple preclinical products, planning to collaborate on more than 10 targets


    Dicerna has worked extensively with MNC on a $3.


    Dicerna has worked extensively with MNC on a $3.


    Dicerna collaborative project

    From: Corporate website

    In 2017, Boehringer Ingelheim partnered with Didrina to develop a non-alcoholic steatohepatitis (NASH) drug


    Boehringer Ingelheim 2017 Non-alcoholic Steatohepatitis (NASH) drug

    In 2018, Alexion partnered with Didrina to develop RNAi therapies


    Alexion Complement-mediated disease in 2018

    In 2019, Roche and Didrina announced a global licensing and research collaboration


    2019 Roche targets chronic hepatitis B virus (HBV) infection

    The hepatitis B gene therapy RG6346 (RO7445482, DCR-HBVS), developed in collaboration with Dicerna and Roche, is currently conducting a joint RG6346 Phase II trial (registration number: NCT04225715)


    RG6346 Gantt chart of global development progress

    From: Insight Database Web

    Previously, Dicerna disclosed data from a Phase I clinical trial of RG6346, which showed that RG6346 produced a substantial, persistent decrease in hepatitis B surface antigen in subjects after 4 months of treatment, and remained


    The PK data for Asian and non-Asian populations remained largely consistent during 1 year follow-up after the last dose

    In November 2019, Novo Nordisk and Dicerna, which have been deeply involved in metabolic diseases for many years, announced a global licensing and research collaboration
    focusing on cardiometabolic diseases.
    Since then, Novo Nordisk has worked closely with Diarna and has explored more than 30 hepatocyte targets involving indications for non-alcoholic steatohepatitis, type 2 diabetes, obesity and more
    .

    Non-alcoholic steatohepatitis, type 2 diabetes, obesity, etc

    But Novo Nordisk did not stop there, acquiring Dicerna in December 2021 for a US$3.
    3 billion investment to further accelerate RNAi drug discovery and expand the use of RNAi technology, becoming one of the highest-premium acquisitions in the pharmaceutical sector that
    year.

    In December 2021, it acquired Dicerna for $3.
    3 billion

    Nordisk acquires Dicerna

    From: Insight Database Web

    Novo Nordisk previously expected to launch clinical development
    of the first target this year.
    According to incomplete statistics, so far in 2022, in addition to the domestic declaration of LY3819469, from a global perspective, there are two other products cooperated with Eli Lilly, LY3849891 and LY3561774 research and development progress to a new stage
    .

    LY3849891, LY3561774 The R&D progress in 2022 has been advanced to a new stage

    From: Insight Database Web

    LY3849891 was first announced overseas in May this year, and is currently conducting a Phase I clinical trial of non-alcoholic fatty liver disease in Japan and the United States (registration number: NCT05395481).

    LY3561774 launched a Phase II clinical study
    in February this year.

    In addition, it is worth mentioning that Alnylam, who has been fighting with Dicerna patent litigation for many years, reached a cooperation with Diarna in April 2020 to develop a drug for the treatment of
    liver disease associated with α-1 antitrypsin (A1AT) deficiency (α-1 liver disease) on ALN-AAT02 and DCR-A1AT 。 In addition, the two companies have agreed to cross-license their respective intellectual property rights for their research programs in Lumasiran and Nedosiran, which treat PH
    .

    Alnylam partnered with Diarna in April 2020

    It is believed that the joint efforts of the two RNAi therapy giants will bring more blockbuster products
    to the RNAi track in the future.

    228 RNAi therapies worldwide in Roche, Novartis, Sanofi.
    .
    .
    Involved in the country

    228 RNAi therapies worldwide in Roche, Novartis, Sanofi.
    .
    .
    Involved in the country

    RNAi is not an emerging technology, but due to its stability, in vivo delivery technology and other reasons, RNAi drug development once fell into a trough, until 2018, the Alnylam RNAi drug ONPATTRO (PATISIRAN) was approved by the FDA for marketing, once again making the RNAi track the focus
    .
    Since then, the RNAi space has been actively
    traded.

    In 2019, Novartis spent $9.
    7 billion to acquire The Medicines Company for Lnclisiran, a cholesterol-lowering RNAi drug;

    In 2020, Blackstone and Alnylam reached a $2 billion funding partnership for R&D in the RNAi industry;

    In 2021, in addition to Novo Nordisk's acquisition of Dicerna, GlaxoSmithKline's collaboration with Arrowhead has also attracted much attention, with GlaxoSmithKline introducing RNAi therapies for NASH for a total of more than $1 billion; .
    .
    .
    .
    .
    .

    At present, according to the Insight database, there are 228 RNAi therapies in the world, 99 of which have entered the clinical stage, of which 5 have been approved for listing, as follows:

    A total of 99 of the 228 RNAi therapies in the global research and clinical stages are in progress

    5 RNAi therapies approved worldwide

    From: Insight Database Web

    For domestic enterprises, it is still in its infancy, with a total of 11 new drugs entering the clinical stage (including declared clinical), of which the fastest growing imported products, including Novartis Inclisiran and Sanofi Fitusiran, have been in the phase III clinical stage; Roche, Johnson & Johnson, Amgen and so on have layouts
    .

    A total of 11 new drugs entered the clinical stage of Novartis Inclisiran, Sanofiro's Johnson & Johnson & Johnson, Amgen

    In addition, the Kotrani introduced by Guangzhou Xiangxue Pharmaceutical has been approved for clinical practice in China in 2017, and the AB-729 introduced by Qilu is still in the clinical stage of
    declaration.

    From the perspective of the layout of domestic enterprises, the field is currently relatively blank, only SR043 and RBD106 of Ruibo Bio and HT101 3 domestic siRNA products of Suzhou Xingyao Kunze Bio have entered the clinical stage (including declared clinical).

    11 domestic RNAi therapies have entered the clinical stage

    From: Insight Database Web

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.